Income Statement Perspective Therapeutics, Inc.
Stocks
CATX
US46489V3024
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.950 USD | -1.01% |
|
0.00% | +7.27% |
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Revenues | 10.05M | 7.1M | 1.43M | 1.45M | 884K | |||||
Total Revenues | 10.05M | 7.1M | 1.43M | 1.45M | 884K | |||||
Cost of Goods Sold, Total | 4.93M | 5.47M | - | 39.43M | 84.22M | |||||
Gross Profit | 5.12M | 1.63M | 1.43M | -37.98M | -83.33M | |||||
Selling General & Admin Expenses, Total | 7.13M | 14.21M | 21.06M | 26.61M | 30.23M | |||||
R&D Expenses | 1.43M | 2.6M | 21.31M | 2.21M | - | |||||
Other Operating Expenses | - | - | - | - | - | |||||
Other Operating Expenses, Total | 8.56M | 16.82M | 42.38M | 28.82M | 30.23M | |||||
Operating Income | -3.44M | -15.18M | -40.94M | -66.8M | -114M | |||||
Interest Expense, Total | - | - | -84K | -48K | -376K | |||||
Interest And Investment Income | 59K | 1.12M | 934K | 10.52M | 8.11M | |||||
Net Interest Expenses | 59K | 1.12M | 850K | 10.47M | 7.74M | |||||
Income (Loss) On Equity Invest. | - | - | -17K | -8K | -2K | |||||
Other Non Operating Income (Expenses) | - | - | 2K | - | 1.4M | |||||
EBT, Excl. Unusual Items | -3.38M | -14.06M | -40.11M | -56.34M | -104M | |||||
Restructuring Charges | - | - | - | - | - | |||||
Impairment of Goodwill | - | - | - | -24.06M | - | |||||
Gain (Loss) On Sale Of Assets | -9K | -610K | - | -27K | - | |||||
Other Unusual Items | - | - | - | - | - | |||||
EBT, Incl. Unusual Items | -3.39M | -14.67M | -40.11M | -80.43M | -104M | |||||
Income Tax Expense | - | - | -2.65M | -2.1M | -793K | |||||
Earnings From Continuing Operations | -3.39M | -14.67M | -37.46M | -78.33M | -104M | |||||
Earnings Of Discontinued Operations | - | - | -9.05M | -949K | 514K | |||||
Net Income to Company | -3.39M | -14.67M | -46.51M | -79.28M | -103M | |||||
Net Income - (IS) | -3.39M | -14.67M | -46.51M | -79.28M | -103M | |||||
Preferred Dividend and Other Adjustments | 3K | - | - | - | - | |||||
Net Income to Common Incl Extra Items | -3.39M | -14.67M | -46.51M | -79.28M | -103M | |||||
Net Income to Common Excl. Extra Items | -3.39M | -14.67M | -37.46M | -78.33M | -104M | |||||
Per Share Items | ||||||||||
Net EPS - Basic | -0.33 | -1.03 | -1.74 | -1.23 | -1.4 | |||||
Basic EPS - Continuing Operations | -0.33 | -1.03 | -1.4 | -1.22 | -1.4 | |||||
Basic Weighted Average Shares Outstanding | 10.38M | 14.21M | 26.76M | 64.42M | 73.81M | |||||
Net EPS - Diluted | -0.33 | -1.03 | -1.74 | -1.23 | -1.4 | |||||
Diluted EPS - Continuing Operations | -0.33 | -1.03 | -1.4 | -1.22 | -1.4 | |||||
Diluted Weighted Average Shares Outstanding | 10.38M | 14.21M | 26.76M | 64.42M | 73.81M | |||||
Normalized Basic EPS | -0.2 | -0.62 | -0.94 | -0.55 | -0.88 | |||||
Normalized Diluted EPS | -0.2 | -0.62 | -0.94 | -0.55 | -0.88 | |||||
Payout Ratio | -0.27 | - | - | - | - | |||||
Supplemental Items | ||||||||||
EBITDA | -3.23M | -14.84M | -39.96M | -64.5M | -110M | |||||
EBITA | -3.38M | -15.11M | -40.91M | -66.8M | -114M | |||||
EBIT | -3.44M | -15.18M | -40.94M | -66.8M | -114M | |||||
EBITDAR | -2.92M | -7.26M | -39.86M | -63.7M | -109M | |||||
Effective Tax Rate - (Ratio) | - | - | 6.61 | 2.61 | 0.76 | |||||
Deferred Domestic Taxes | - | - | -2.65M | -2.1M | -793K | |||||
Total Deferred Taxes | - | - | -2.65M | -2.1M | -793K | |||||
Normalized Net Income | -2.11M | -8.79M | -25.07M | -35.21M | -65.27M | |||||
Interest on Long-Term Debt | - | - | 84K | - | - | |||||
Supplemental Operating Expense Items | ||||||||||
Marketing Expenses | 84K | 126K | - | - | - | |||||
Selling and Marketing Expenses | 2.44M | 3.23M | - | - | - | |||||
General and Administrative Expenses | 4.58M | 10.87M | 20.97M | 25.81M | 29.13M | |||||
Research And Development Expense From Footnotes | 1.43M | 2.6M | 21.31M | 41.64M | 84.22M | |||||
Net Rental Expense, Total | 304K | 161K | 97K | 800K | 1.1M | |||||
Imputed Operating Lease Interest Expense | - | - | - | 92.9K | 905K | |||||
Imputed Operating Lease Depreciation | - | - | - | 707K | 195K | |||||
Stock-Based Comp., COGS (Total) | 30K | 28K | - | - | 3.94M | |||||
Stock-Based Comp., R&D Exp. (Total) | 104K | 316K | 968K | 2.21M | - | |||||
Stock-Based Comp., S&M Exp. (Total) | 49K | 94K | - | - | - | |||||
Stock-Based Comp., G&A Exp. (Total) | 203K | 906K | 2.18M | 3.01M | 5.02M | |||||
Stock-Based Comp., Other (Total) | - | - | - | - | - | |||||
Total Stock-Based Compensation | 386K | 1.34M | 3.14M | 5.22M | 8.97M |
- Stock Market
- Stocks
- CATX Stock
- Financials Perspective Therapeutics, Inc.
- Income Statement
Select your edition
All financial news and data tailored to specific country editions
















